Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571027 | 0.90 | KCNH3 (0.58) | KCNH3ALDH1A1SMN1; SMN2MAPK1HTT | |
| Water SCHEMBL4690707 | 0.88 | KCNH3 (0.57) | KCNH3ALDH1A1SMN1; SMN2MAPK1HTT | |
| SCHEMBL12523516 | 0.78 | ALDH1A1 (0.55) | KCNH3ALDH1A1SMN1; SMN2MAPK1HTT | |
| SCHEMBL22752683 | 0.73 | ALDH1A1 (0.51) | KCNH3ALDH1A1SMN1; SMN2MAPK1HTT | |
| SCHEMBL12459209 | 0.73 | ALDH1A1 (0.51) | KCNH3ALDH1A1SMN1; SMN2MAPK1HTT | |
| SCHEMBL30181846 | 0.72 | ALDH1A1 (0.52) | KCNH3ALDH1A1SMN1; SMN2MAPK1HTT | |
| SCHEMBL29952698 | 0.71 | ALDH1A1 (0.52) | KCNH3ALDH1A1MAPK1KMT2ANPC1 | |
| SCHEMBL13647720 | 0.71 | KCNH3 (0.46) | KCNH3ALDH1A1SMN1; SMN2MAPK1HTT | |
| SCHEMBL27758374 | 0.70 | UTS2R (0.52) | KCNH3ALDH1A1SMN1; SMN2MAPK1HTT | |
| SCHEMBL25951848 | 0.69 | ALDH1A1 (0.47) | KCNH3ALDH1A1SMN1; SMN2MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480973-B1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7041669-B2 | 1,4-benzofused urea compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1480973-A1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030232865-A1 | 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003072569-A1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232865-A1 | 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases | IL1A, IL1B, XDH | KCNH3 4628/4885ALDH1A1 63/4885SMN1; SMN2 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.